Bevacizumab is a recombinant humanized monoclonal antibody that blocks the VEGF to bind with its receptor VEGFR on the surface of endothelial cells. The prevention of binding VEGF with VEGFR leads to the inhibition of new blood vessel formation known as angiogenesis that feeds the cancer cells. Thus, Bevacizumab stops the growth & metastasis of different types of cancer. Bevacizumab significantly increases OS & PFS in cancer patients when given with chemotherapy.
Bevacizumab is used to treat versatile types of cancer like Metastatic Colorectal Cancer (mCRC); Metastatic Non-Squamous Non-Small Cell Lung Cancer (mNSCLC); Recurrent Glioblastoma (rGBM); Metastatic Renal Cell Carcinoma (mRCC); Persistent, Recurrent, or Metastatic Cervical Cancer (CC); Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer & Hepatocellular Carcinoma (HCC).
FR
DE